Coronavirus Takes Its Toll on Alzheimer’s Clinical Studies
Most observational cohorts are on pause, and many clinical trials have stopped dosing. The long-term effects on the integrity of AD studies are unclear.
ALL NEWS
6513 RESULTS
Sort By:
- Most Recent
- Most Commented
First Evidence for Transmitted Alzheimer’s Disease?
Eight adults who, as children, had received growth hormone from cadavers developed cognitive problems and/or AD-like pathology in midlife.
Behold PANTHOS, a Toxic Wreath of Perinuclear Aβ That Kills Neurons
Months before mice develop plaques, faulty lysosomes swollen with Aβ commandeer plasma, ER, and Golgi membranes, creating toxic rosettes around the nucleus. The neurons eventually burst, leaving behind plaques.
What About the Brain Shrinkage Seen with Aβ Removal?
Anti-amyloid therapy could compromise brain health, a meta-analysis claims. Others say the concern is overblown.
Dare We Say Consensus Achieved: Lecanemab Slows the Disease
Scientists at CTAD found the Phase 3 trial well-done, the data consistent, and expect the drug to be approved. Priorities: grow the effect, understand the bleeding risk.
Aducanumab Still Needs to Prove Itself, Researchers Say
While the FDA weighs aducanumab’s marketing license application, Alzheimer’s researchers agree that the agency’s own statistician correctly assessed the data as weak. Most prefer that one more trial be done.
‘Reports of My Death Are Greatly Exaggerated.’ Signed, Aducanumab
After shutting down a Phase 3 program last March, Biogen now says the futility analysis it did was incorrect, and that a new analysis of a larger dataset in fact supports filing for FDA marketing approval next year.
A Country Doctor, But Oh So Much More: Francisco Lopera, 73
The indefatigable Colombian neurologist leaves behind a legacy of Alzheimer’s prevention research, which, at the time of his passing, stands on the cusp of success.
Familial AD Mutations, β-CTF, Spell Trouble for Endosomes
Using a collection of isogenic iPSC-derived neurons harboring different familial AD mutations, researchers found that, across the board, the mutations meddled with endosomes via elevated β-CTF.
Field Says Farewell to Neuropathologist Yasuo Ihara, 78
A giant of basic science, Ihara biochemically characterized Aβ and tau deposits in AD brain, laying the groundwork for subsequent discoveries.
Bapineuzumab Phase 3: Target Engagement, But No Benefit
Bapineuzumab prevents accumulation of Aβ in the brain and lowers phospho-tau (p-tau) in cerebrospinal fluid (CSF), according to analysis...
Anne Cataldo, 57, Autophagy Researcher Known for Generous Collegiality
It is with deep sadness that we inform the Alzheimer research community of the passing of Anne Cataldo...
Field Loses Another Pioneer with Passing of Allen Roses, 73
Discoverer of ApoE4 risk allele died of a heart attack.
New Definition of Alzheimer’s Hinges on Biology, Not Symptoms
For the first time, NIA-AA proposal bases diagnosis in living people solely on biomarkers for plaques and tangles.
Colleagues Mourn Loss of Rahul Desikan, Age 41, to ALS
Desikan pioneered advances in neuroimaging and neurogenetics, and was known for his passion and collaborative spirit.
Current Filters
No filters selected